FY2024 Earnings Forecast for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Stock analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for IQVIA in a research report issued on Tuesday, December 10th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings per share of $10.13 for the year, up from their previous forecast of $10.07. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2026 earnings at $12.26 EPS and FY2027 earnings at $13.70 EPS.

Other research analysts have also recently issued reports about the company. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. TD Cowen cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Wednesday. Finally, Morgan Stanley cut their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $256.19.

IQVIA Stock Down 0.7 %

Shares of IQV stock opened at $199.06 on Friday. The stock has a market cap of $36.13 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49. IQVIA has a one year low of $187.62 and a one year high of $261.73. The stock has a fifty day moving average price of $212.86 and a 200 day moving average price of $224.44. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently modified their holdings of the stock. Oddo BHF Asset Management Sas acquired a new position in shares of IQVIA during the 3rd quarter worth about $2,771,000. Franklin Resources Inc. grew its position in shares of IQVIA by 1.2% during the 3rd quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company’s stock worth $117,031,000 after buying an additional 6,011 shares during the period. Tidal Investments LLC grew its position in shares of IQVIA by 9.3% during the 3rd quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company’s stock worth $1,417,000 after buying an additional 509 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of IQVIA during the 3rd quarter valued at about $2,310,000. Finally, Arvest Bank Trust Division bought a new position in shares of IQVIA during the 3rd quarter valued at about $21,079,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.